GUTS — Fractyl Health, Inc.
Is GUTS overbought or oversold? Here is the current MarketMoodz read.
Fractyl Health, Inc. (GUTS) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $0.99. The rating moved from Strong Oversold to Oversold on November 17, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$0.99
- Last changeMoved from Strong Oversold to Oversold on November 17, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Fractyl Health, Inc. (GUTS) appears to be an early-stage, capital-dependent healthcare issuer with limited public financial transparency. The company faces near-term funding and execution risk, with outcomes driven by clinical and regulatory progress or the ability to secure strategic partnerships. Broader sector flows currently favor large-cap defensive pharma and specific outpatient care themes, which reduces immediate investor focus on speculative microcaps. Absent clear filings, upcoming catalysts, or secured financing, the company’s outlook is highly binary: positive clinical or commercial news and/or partnership/financing could materially improve prospects, while delays, negative data, or further dilution would likely pressure the share price.
Key factors
- Limited public financial disclosure and no recent EDGAR comparisons available, increasing uncertainty about cash runway and revenue generation
- Small-cap / early-stage profile with likely negative operating cash flow and dependence on financing or partnerships to fund operations
- Healthcare sector tailwinds are mixed; broader rotation favors large-cap pharma and certain outpatient care shifts rather than highly speculative microcaps
- Potential readthroughs from sector themes (home/outpatient care, diabetes device competition) could present partnership or licensing opportunities if clinical/commercial assets align
- Market sentiment is cautiously optimistic overall, but investor focus is on earnings and larger-cap healthcare names rather than speculative small issuers
Risks
- High dilution risk from future equity or convertible financings to cover burn
- Regulatory and clinical-development execution risk (trial delays, negative outcomes, or longer approval timelines)
- Limited liquidity in the stock leading to volatile price moves and wide bid-ask spreads
- Reimbursement and commercial adoption risk if product candidates require payer coverage to achieve meaningful revenue
- Competitive pressure from larger, better-capitalized medical device and therapeutics companies in adjacent metabolic and GI-related markets
See today's live rating, score and targets
Members see the live hourly rating for GUTS — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.